Melbourne-based respiratory imaging technology company 4DMedical concluded its acquisition of Imbio, a US-based medical technology firm specialising in AI-driven lung and heart diagnostic products, including four Food and Drug Administration-cleared offerings.

The move significantly expands 4DMedical's product portfolio, providing clinicians with an enhanced suite of diagnostic tools.

The transaction is also expected to advance efforts in early disease detection.

Imbio is projected to generate $3 million in revenue in 2023 and $6.3 million in 2024 and achieve positive cash flow within the first year post-integration.